Patents by Inventor Hernan Orgueira

Hernan Orgueira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7994304
    Abstract: The invention provides a family of tethered nucleotide analogs useful in sequencing nucleic acids containing a homopolymer region comprising, for example, two or more base repeats, and to sequencing methods using such tethered nucleotide analogs.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: August 9, 2011
    Assignee: Helicos Biosciences Corporation
    Inventors: Suhaib Siddiqi, Hernan Orgueira, Edyta Olejnik, Subramanian Marappan, Philip R. Buzby, Atanu Roy
  • Publication number: 20080227970
    Abstract: The invention provides a family of tethered nucleotide analogs useful in sequencing nucleic acids containing a homopolymer region comprising, for example, two or more base repeats, and to sequencing methods using such tethered nucleotide analogs.
    Type: Application
    Filed: October 30, 2007
    Publication date: September 18, 2008
    Applicant: Helicos BioSciences Corporation
    Inventors: Suhaib Siddiqi, Hernan Orgueira, Edyta Kvzymanska-Olejnik, Subramanian Marappan, Philip R. Buzby, Atanu Roy
  • Publication number: 20080103053
    Abstract: The invention provides a family of tethered nucleotide analogs useful in sequencing nucleic acids containing a homopolymer region comprising, for example, two or more base repeats, and to sequencing methods using such tethered nucleotide analogs.
    Type: Application
    Filed: May 14, 2007
    Publication date: May 1, 2008
    Applicant: Helicos BioSciences Corporation
    Inventors: Suhaib Siddiqi, Hernan Orgueira, Edyta Krzymanska-Olejnik, Subramanian Marappan, Philip R. Buzby, Atanu Roy
  • Publication number: 20070027190
    Abstract: Disclosed herein are antibacterial compounds that inhibit fabl, a NADH-dependent enoyl [acyl carrier protein] reductase enzyme in the fatty acid biosynthesis pathway. The compounds are represented by structural formulas Ia and Ib: R1 and R2 are independently monocyclic aryl or heteroaryl groups, wherein the groups represented by R1 and R2 are optionally substituted with one or more acyclic substituents; R3 is —H or an optionally substituted C1-C8 aliphatic, C3-C8 cycloaliphatic, aryl, or heteroaryl group. X1 is a bond or a C1-C3 alkylene chain that is optionally substituted with a C1-C4 alkyl or an acidic group. X2 is an aryl, heteroaryl or C3-C8 cycloaliphatic ring, wherein the group represented by X2 is optionally substituted with triazole, tetrazole, and/or one or more acyclic substituents.
    Type: Application
    Filed: January 16, 2004
    Publication date: February 1, 2007
    Inventors: Donald Moir, Yibin Xiang, Anthony Arvanites, Syed Ali, Bolin Geng, Mark Ashwell, Hernan Orgueira, Alan Kaplan
  • Publication number: 20050187381
    Abstract: Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction processes. The determination of specific sequences involved in receptor binding holds great promise for the development of molecular tools which will allow modulation of processes underlying viral entry, angiogenesis, kidney diseases and diseases of the central nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.
    Type: Application
    Filed: January 21, 2005
    Publication date: August 25, 2005
    Inventors: Peter Seeberger, Hernan Orgueira, Peter Schell
  • Patent number: 6846917
    Abstract: Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction processes. The determination of specific sequences involved in receptor binding holds great promise for the development of molecular tools which will allow modulation of processes underlying viral entry, angiogenesis, kidney diseases and diseases of the central nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: January 25, 2005
    Assignee: Massachusetts Institute of Technology
    Inventors: Peter H. Seeberger, Hernan Orgueira, Peter Schell
  • Publication number: 20030013862
    Abstract: Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction processes. The determination of specific sequences involved in receptor binding holds great promise for the development of molecular tools which will allow modulation of processes underlying viral entry, angiogenesis, kidney diseases and diseases of the central nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.
    Type: Application
    Filed: January 22, 2002
    Publication date: January 16, 2003
    Inventors: Peter H. Seeberger, Hernan Orgueira, Peter Schell